Marathon Trading Investment Management LLC Trims Stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Marathon Trading Investment Management LLC lowered its position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 79.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,225 shares of the company’s stock after selling 71,775 shares during the period. Marathon Trading Investment Management LLC’s holdings in Aquestive Therapeutics were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of AQST. Janney Montgomery Scott LLC bought a new stake in shares of Aquestive Therapeutics during the 1st quarter worth approximately $1,456,000. Vanguard Group Inc. increased its stake in Aquestive Therapeutics by 71.7% in the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after purchasing an additional 1,353,518 shares during the period. Jump Financial LLC bought a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $60,000. Lazard Asset Management LLC boosted its stake in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after purchasing an additional 15,601 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Aquestive Therapeutics in the first quarter worth about $54,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Price Performance

NASDAQ:AQST opened at $4.95 on Thursday. The firm has a market cap of $450.64 million, a PE ratio of -11.79 and a beta of 2.84. The company has a 50-day moving average of $3.93 and a 200 day moving average of $3.69. Aquestive Therapeutics, Inc. has a 1-year low of $1.25 and a 1-year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.08. The business had revenue of $20.10 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same period in the previous year, the company posted ($0.10) EPS. Sell-side analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on AQST. HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a report on Wednesday, August 14th. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a research note on Monday, August 12th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $7.83.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.